Mumbai: Sun Pharmaceutical Industries has got nod from USFDA to promote the generic version of Novartis’s Exelon capsules ‘Rivastigmine Tartrate.’
Rivastigmine Tartrate is used for the treatment of Alzheimer’s and Parkinson’s disease.
Sun gets FDA authorization for 1.5mg, 3mg, 4.5mg and 6mg drug potencies.
The yearly sales of Exelon capsules in the US market would be around $200 million in these strengths.